Research Article

Application of Fluorescence Dye in Combination with Methylene Blue for Axillary Reverse Mapping in Patients with Modified Radical Mastectomy for Breast Cancer

Haiyi Wang,1,2 Baochao Wu,1,2 and Zheng Wang1,3

1Department of Thyroid and Breast Surgery, Tongling people’s hospital, Tongling, Anhui 244009, China
2Department of Thyroid and Breast Surgery, Tongling Branch of the First Affiliated Hospital of University of Science and Technology of China, Tongling, Anhui 244009, China
3Department of Vascular Surgery, Tongling Branch of the First Affiliated Hospital of University of Science and Technology of China, Anhui 244009, China

Correspondence should be addressed to Zheng Wang; wangzdr@yeah.net

Received 14 February 2022; Accepted 1 April 2022; Published 14 May 2022

Academic Editor: Dong-Hua Yang

Copyright © 2022 Haiyi Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Axillary reverse mapping (ARM) is a novel intraoperative technique developed in recent years. This study was aimed at determining the effect of combined use of fluorescence dye and methylene blue, as well as its feasibility of ARM in patients with breast cancers who undergo modified radical mastectomy.

Method. From January 2016 to June 2017, 46 patients with primary breast cancer at stage I-IV (Tis-T3, N0-N3, and M0) who received modified radical mastectomy were enrolled in this study. The exclusion criteria included preoperative radiotherapy/chemotherapy or bilateral disease. Patients were divided into 2 groups: methylene blue group (22 patients, 47.8%) and methylene blue+indocyanine green (ICG) group (24 patients, 52.2%). ARM was performed before surgery.

Results. The overall visualization rate of ARM nodes was 80.4% (37/46). The visualization rate was significantly increased in methylene blue+ICG group (91.67%, 22/24) than that in methylene blue group (63.64%, 14/22) (P = 0.032). There was a statistical difference of visualization rate between clinical groups of N0-N1 and N3-N4 (t = 2.431, P = 0.019 < 0.05). Although there was no significant difference found in the total drainage volume and arm perimeter of patients between the two groups (P > 0.05), the harden diameter of the injection site in methylene blue+ICG group was significantly longer than that in methylene blue group (P < 0.05). Among the 44 patients with different molecular profiling of breast cancer, there was no significant difference of visualization rate of ARM nodes in luminal A group (100%,5/5), luminal B group (75.0%, 18/24, P = 0.21), HER2 group (75.0%, 6/8, P = 0.22), and basal-like group (85.7%, 6/7, P = 0.37). Conclusions. ARM using methylene blue+ICG presented greater identification rate than that with methylene blue alone, especially in patients with more invasive breast cancer. Our finding offers support for the improvement of ARM in future breast cancer management.

1. Introduction

Although new markers for oncogene expression were identified and showed promise in guiding treatment strategies for breast cancer, the condition of the axillary lymph nodes affects treatment and remains one of the most important prognostic factors of outcome [1]. Currently, axillary lymph node dissection (ALND) represents the standard treatment for patients with metastatic axillary lymph nodes. However, ALND has high incidence of upper extremity lymphedema, ranging from 7% to 77%, and arm/shoulder dysfunction, paresthesia, and discomfort are found after the surgery [2]. Sentinel lymph node biopsy (SLNB) is recommended for patients with clinically node-negative axilla at surgery, which significantly decreases surgical complications compared with ALND [3, 4]. Nevertheless, several reports on clinical trial
have shown that the rate of lymphedema was approximately 7% with SLNB alone [5].

Axillary reverse mapping (ARM) is a technique described initially by Thompson et al. [6] and Nos et al. [7] in 2007, to delineate the lymph nodes (named ARM nodes) and lymphatic vessels of the upper limb during the axillary surgery in breast cancer patients. In this technique, the ARM nodes can be spotted by injecting a tracer into the upper arm prior to surgery, similar to the identification of the sentinel lymph node (SLN) that drains the breast [6]. The ultimate aim of ARM is to limit the occurrence of arm lymphedema based on the hypothesis that the ARM procedure actually identifies a different lymphatic pathway coming from the arm [5]. The addition of ARM to ALND or SLNB may reduce lymphedema of the upper extremity by preserving upper extremity drainage. So far, three visualization methods have been used in ARM, such as

![Figure 1: Subcutaneous injection of ICG into the ipsilateral upper inner arm.](image)

| Characteristics | Methylene blue+ICG (24) | Methylene blue (22) | $P$ | Characteristics | Methylene blue+ICG (24) | Methylene blue (22) | $P$ |
|-----------------|------------------------|--------------------|-----|-----------------|------------------------|--------------------|-----|
| Median age      | 48 (34–77)             | 51 (37–68)         |     | HER2            | 0.375                  |                     |     |
|                 |                        |                    |     | Negative        | 15                     | 10                 |     |
|                 |                        |                    |     | Positive        | 9                      | 12                 |     |
| Histologic type | 0.987                  |                     |     | Inv. ductal     | 15                     | 15                 |     |
|                 |                        |                    |     | Inv. lobular    | 5                      | 6                  |     |
|                 |                        |                    |     | Mix             | 4                      | 1                  |     |
| Clinical staging| 0.421                  |                     |     | Inv. ductal     | 15                     | 15                 |     |
|                 |                        |                    |     | Inv. lobular    | 5                      | 6                  |     |
|                 |                        |                    |     | Mix             | 4                      | 1                  |     |
| Topo II         | 0.484                  |                     |     | Negative        | 15                     | 15                 |     |
|                 |                        |                    |     | Positive        | 15                     | 15                 |     |
| GST-π           | 0.92                   |                     |     | Clinical T stage| 13                     | 13                 |     |
|                 |                        |                    |     | T1              | 13                     | 13                 |     |
|                 |                        |                    |     | T2              | 11                     | 11                 |     |
| Ki67 score      | 0.716                  |                     |     | Clinical N stage| 1                       | 1                  |     |
|                 |                        |                    |     | N0              | 10                     | 10                 |     |
|                 |                        |                    |     | N1              | 10                     | 6                  |     |
|                 |                        |                    |     | N2              | 3                      | 2                  |     |
|                 |                        |                    |     | N3              | 1                      | 3                  |     |

Table 1: Clinicopathological characteristics of patients.
The blue dye is the most commonly used way, whereas only five studies have reported the application of fluorescent dye indocyanine green (ICG) so far. In this study, the effect of combined use of blue dye and ICG is assessed during the modified radical mastectomy on patients with breast cancers.

2. Patients and Methods

2.1. Study Cohort. From January 2016 to June 2017, 46 patients who underwent modified radical mastectomy were enrolled in this study. They were diagnosed as primary breast cancer at clinical stage I-IV (Tis-T3, N0-N3, and M0) in our hospital. Those with preoperative radiotherapy/chemotherapy or bilateral disease were excluded. Ethical approval for this study was provided by the local ethical committee of our hospital. The median age of the study cohort was 50 years old (range 34-77). Informed consent was obtained from each patient prior to surgery.

Patients were divided into 2 groups. The control group (methylene blue group) consisted of patients receiving ARM using methylene blue alone (22 patients, 47.8%). The experiment group (methylene blue+ICG group) received the combination of ICG and methylene blue (24 patients, 52.2%). In the methylene blue group, 2.0 ml of methylene blue (Jumpcan Pharmaceutical Group Co., Ltd., Jiangsu, China, medicine number: H32024827) was subcutaneously injected into the upper inner arm. Then, the injection site was massaged, and the arm was raised for 10 min until the blue lymphatic vessels were observed in the upper extremity. Similar procedure was used in the methylene blue+ICG group for injection of 2.0 ml methylene blue plus 5 mg ICG (Tianyi Biopharmaceutical Co., Ltd., Liaoning, China, medicine number:H20045514). The clinical characteristics of the study cohort were summarized in Table 1.

2.2. Axillary Reverse Mapping. The axillary reverse mapping (ARM) technique is developed for identifying and preserving lymphatic drainage from the arm during ALND. ARM was performed before the surgery. Before ALND, 2.0 ml of methylene blue with or without 5 mg of ICG in 2 ml of normal saline (NS) was subcutaneously injected into the ipsilateral upper inner arm of experiment or control group, respectively (Figure 1). The injection site was massaged gently for 10 min after the injection.

2.3. Axillary Lymph Node Dissection. The primary ALND was indicated based on enlarged axillary lymph nodes by imaging assessment. ARM node labeled with ICG was observed by a fluorescence imaging camera (Langfang Minge Biological Medical Technology Co., Ltd., Hebei, China), while methylene blue was viewed with the naked eyes (Figures 2 and 3). Intraoperative identification rates of ARM nodes as well as the metastasis rates of ARM nodes were then evaluated. During the surgery, ARM nodes were first identified and removed separately and then examined by pathologic tests.

2.4. Pathological Examination. All patients were diagnosed with the evaluation of postoperative TNM stage based on the revised TNM staging system adopted by NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 1.2016).

Molecular profiling of breast cancer was performed for each patient and identified as luminal A, luminal B, basal-like, and overexpressed HER2 type and the estrogen/progesterone receptor (ER/PR) status as well as HER2/neu status.

2.5. Statistical Analysis. Statistical analysis was conducted by using SPSS, version 17.0. The chi-square and T test analysis were used to estimate intergroup differences. A P value < 0.05 was considered to be statistically different.
3. Results

3.1. Successful Rate of Methylene Blue or Methylene Blue + ICG Dyeing. The overall successful dyeing rate of ARM nodes was 80.4% (36/46). 22 patients received dyeing of methylene blue alone, while 24 patients were given treatment of methylene blue+ICG. Visualization rate was significantly higher in the methylene blue+ICG (91.67%, 22/24) group than that in the methylene blue alone group (63.64%, 14/22) \((P = 0.032)\). Moreover, among the 24 patients in the methylene blue+ICG group, the diagnosis result on lymph node showed that 20 (83.31%) cases belonged to clinical N0-N1 and 4 (16.67%) cases to clinical N3-N4, while in the methylene blue group, 16 (76.19%) belonged to clinical N0-N1 and 5 (23.81%) to clinical N3-N4. The differences of clinical N0-N1 stage and N3-N4 stage between methylene blue group and methylene blue+ICG group presented statistically significant \((t = 2.431, P = 0.19)\).

3.2. Postoperative Drainage Volume. The total drainage volume includes parasternal drainage volume and axillary drainage volume. We observed that the total drainage volume in the methylene blue+ICG group was slightly lower than that of the methylene blue group, though the difference was insignificant \((P > 0.05)\) (Table 2).

3.3. Postoperative Perimeter of Limb. There was no significant difference in the total hospital days required for patients in these two groups \((P > 0.05)\). The difference of limb perimeter between the patients in the group of methylene blue+ICG was to some extent higher than that in methylene blue group from day 1 to day 6. At days 7 and 8, perimeter difference of the two groups tended to be consistent (Figure 4 and Table 3).

3.4. Postoperative Harden Diameter of the Injection Site. From day 1 to day 8, the harden diameter, which is the blue tattooing that occurs at the injection site, exhibited the large tendency in the methylene blue+ICG group compared to that of methylene blue group. Of note, from day 3 to day 8, there was significant difference of harden diameter of the injection site between the two groups after the surgery \((P < 0.05)\) (Figure 5 and Table 4).

3.5. Positive Rate of Lymph Node. In the methylene blue group, the number of positive axillary lymph node dissections was 11 (11/22,50%), and in the methylene blue+ICG group, the number was 11 (11/24,45.83%), indicating that the positive rate of lymph node in methylene blue+ICG group was slightly lower than that of methylene blue group (Table 5).

4. Discussion

The concept underlying the ARM technique assumes that lymphatics draining the upper extremity are not involved in the metastasis of the primary breast tumor [5, 6]. However, those studies also reported the incidence of metastatic tumor in the ARM nodes is 14%-43%. Currently, most of
In addition, the visualization rates during SLNB were 43% to 90% while of ARM lymphatics ranged from 20% to 47% [10, 11]. Alternatively, a pilot study using the fluorescent dye ICG described that the visualization rates of the ARM lymph nodes and the ARM lymphatics in the ALND field were 88 and 63%, respectively [12]. In the same study, visualization of the ARM lymph nodes and the ARM lymphatics during SLNB was only 43 and 19%, respectively.

In our study, the identification rate of the ARM node was 80.4%, which is similar to 61% by Thompson et al. [6], 75% by Kumar et al. [8], and 71% by Nos et al. [7]. Our data on visualization rate in methylene blue+ICG group (91.67%, 22/24) was significantly higher than that in methylene blue alone group (63.64%, 14/22). Particularly, there are significant differences of visualization rate between the two groups at stage of clinical N0-N1 and N3-N4 ($t = 2.431, P = 0.19 < 0.05$). These findings suggested that methylene blue+ICG could improve identification rate of ARM node, especially for patients with more invasive breast cancer.

Although there were no statistical differences in the total drainage volume and perimeter difference between ICG +methylene blue group and methylene blue alone group, the harden diameter of the injection site was significantly increased in methylene blue+ICG group than that in methylene blue alone group. These results indicate the feasibility of ARM using fluorescence+blue dye over blue dye alone in the Chinese breast cancers patients who received modified radical mastectomy.

5. Conclusions

ARM using methylene blue+ICG presents greater identification rate of ARM node than that with methylene blue alone, which provides a potential tool for the surgical therapy towards patients with invasive breast cancer.

**Data Availability**

Emails could be sent to the address below to obtain the shared data: wangzdr@yeah.net

**Conflicts of Interest**

The authors declare that they have no conflict of interest.

**Acknowledgments**

This work was supported by the Department of Thyroid and Breast Surgery and the Tongling Branch of the First Affiliated Hospital of University of Science and Technology of China. The author is very grateful to Dr. Zheng Wang.
Graduate Teacher Research Supervisor, for the guidance with writing the manuscript. This work was also supported by grants from the Anhui Scientific and Technological Research (1604a0802096).

References

[1] A. H. Narasannaiah, A. Z. Anwar, K. V. Manjunath et al., "Reverse axillary mapping in breast cancer using blue dye: a tertiary setup experience," *Cureus*, vol. 13, no. 10, article e18576, 2021.

[2] M. A. Beek, P. D. Gobardhan, E. J. Schoenmaeckers et al., "Axillary reverse mapping in axillary surgery for breast cancer: an update of the current status," *Breast Cancer Research and Treatment*, vol. 158, no. 3, pp. 421–432, 2016.

[3] W. J. Gradishar, B. O. Anderson, R. Balassanian et al., "Breast cancer version 2.2015," *Journal of the National Comprehensive Cancer Network*, vol. 13, no. 4, pp. 448–475, 2015.

[4] G. H. Lyman, M. R. Somerfield, L. D. Bosserman, C. L. Perkins, D. L. Weaver, and A. E. Giuliani, "Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update," *Journal of Clinical Oncology*, vol. 35, no. 5, pp. 561–564, 2017.

[5] D. Pavlista, L. Dostalek, and Z. Velenska, "Axillary Reverse Mapping in Breast Cancer Surgery - Functional Study," *Neoplasma*, vol. 69, no. 2, pp. 425–429, 2022.

[6] M. Thompson, S. Korourian, R. Henry-Tillman et al., "Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation," *Annals of Surgical Oncology*, vol. 14, no. 6, pp. 1890–1895, 2007.

[7] C. Nos, B. Lesieur, K. B. Clough, and F. Lecuru, "Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection," *Annals of Surgical Oncology*, vol. 14, no. 9, pp. 2490–2496, 2007.

[8] K. S. Kumar, G. N. Hemanth, P. K. Panjwani et al., "Feasibility of axillary reverse mapping and clinicopathological features predicting ARM node metastasis in breast cancer-a pilot study," *Indian Journal of Surgical Oncology*, vol. 8, no. 2, pp. 119–122, 2017.

[9] P. D. Gobardhan, E. G. Klompenhouwer, M. A. Beek, A. C. Voogd, and E. J. Luiten, "Axillary reverse mapping: preserving nodes during an axillary lymph node dissection," *Nederlands Tijdschrift voor Geneeskunde*, vol. 157, no. 22, article A5646, 2013.

[10] U. Kuusk, N. Seyednejad, E. C. McKevitt, C. K. Dingee, and S. M. Wiseman, "Axillary reverse mapping in breast cancer: a Canadian experience," *Journal of Surgical Oncology*, vol. 110, no. 7, pp. 791–795, 2014.

[11] C. Connor, M. McGinness, J. Mammen et al., "Axillary reverse mapping: a prospective study in women with clinically node negative and node positive breast cancer," *Annals of Surgical Oncology*, vol. 20, no. 10, pp. 3303–3307, 2013.

[12] M. Noguchi, M. Yokoi, and Y. Nakano, "Axillary reverse mapping with indocyanine fluorescence imaging in patients with breast cancer," *Journal of Surgical Oncology*, vol. 101, no. 3, pp. 217–221, 2010.